GlaxoSmithKline: Phase 3 study in Cardiovascular Disease (16390 participants)
GlaxoSmithKline: Phase 3 study in Cardiovascular Disease (16390 participants). Its enrollment of 16,390 is top-decile (99th percentile of 8,879 records). Dated 23 days ago, it is in the active follow-up window. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 16,390 · 99th percentile of 8,879 ClinicalTrialStartPulse records · 204.9x the median
Free preview: all 13 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | GlaxoSmithKline |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors |
| NCT ID | NCT07872046 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Cardiovascular Disease |
| Intervention types | combination product |
| Target enrollment | 16390 |
| Posted | 2026-10-13 |
| Planned start | 2026-11-30 |
| Event | Newly registered study |
| Event date | 2026-10-13 |
| enrollment percentile | 99th of 8,879 (median 80, 204.9x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch GlaxoSmithKline
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock GlaxoSmithKline + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-13
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: GlaxoSmithKline and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- GlaxoSmithKline's enrollment: 99th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 16390 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for GlaxoSmithKline?
GlaxoSmithKline registered a Phase 3 study (NCT07872046) in Cardiovascular Disease targeting 16390 participants, posted 2026-10-13.
How does GlaxoSmithKline compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 16,390 is 204.9x the median of 80 across 8,879 records. It is 23 days old, still within a typical 45-day follow-up window. Its Score of 75/100 puts it among the stronger signals in this feed.
GlaxoSmithKline vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| GlaxoSmithKline | NONUS | 16,390 | 99th | 2026-10-13 |
| Merck Sharp & Dohme LLC | US | 1,104 | 95th | 2026-11-03 |
| Janssen Research & Development, LLC | US | 864 | 93rd | 2026-11-03 |
| Janssen Research & Development, LLC | US | 743 | 92nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor GlaxoSmithKline and peer phase 3 records
Get new ClinicalTrialStartPulse records like GlaxoSmithKline by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.